Li Gan, PhD, wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.
When researchers like Gan find potential new drugs, it’s useful to test them on human cells to increase the chances that they will benefit patients. Historically, these tests have been conducted in cancer cells, which often don’t match the biology of human brain cells.
“The problem is that brain cells from actual people don’t survive well in a dish, so we need to engineer human cells in the lab,” explained Gan, senior investigator at the Gladstone Institutes. “But, that’s not as simple as it may sound.”
Many scientists use induced pluripotent stem cells (iPSCs) to address this issue. IPSCs are made by reprogramming skin cells or blood cells to become stem cells, which can then be transformed into any type of cell in the body. Gan uses iPSCs to produce brain cells, such as neurons or glial cells, because they are relevant to neurodegenerative disease.
Human brain cells derived from iPSCs offer great potential for drug screening. Yet, the process for producing them can be complicated, expensive, and highly variable. Many of the current methods produce cells that are heterogeneous, or different from one another, and this can lead to inconsistent results in drug screening. In addition, producing a large number of cells is very costly, so it’s difficult to scale up for big experiments.
A new platform developed in Gan’s lab will now allow scientists to overcome these constraints
A New Technique Is Born
“I came across a new method to produce iPSCs that was developed at Stanford,” said Michael Ward, MD, PhD, a former staff scientist in Gan’s lab who is now an investigator at the National Institutes of Health. “I thought that if our team could find a way to simplify and better control that approach, we might be able to improve the way we engineer human brain cells in the lab.”
Ward and his colleague Chao Wang, PhD, discovered a way to manipulate the genetic makeup of cells to produce thousands of neurons from a single iPSC. This meant that every engineered brain cell was now identical.
“I was truly motivated by our initial results,” said Gan, who is also a professor of neurology at UC San Francisco. “I had observed too much variability using the traditional methods, which made reproducing experiments quite problematic. So, the ability to produce homogeneous human brain cells was very exciting.”
The team further improved the technique to create a simplified, two-step process. This allows scientists to precisely control how many brain cells they produce and makes it easier to replicate their results from one experiment to the next.
Their technique also greatly accelerates the process. While it would normally take several months to produce brain cells, Gan and her team can now engineer large quantities of them within 1 or 2 weeks, and have functionally active neurons within 1 month.
The researchers realized this new approach had tremendous potential to screen drugs and to study disease mechanisms. To prove it, they tested it in their own research.
They applied their technique to produce human neurons by using iPSCs. Then, they developed a drug discovery platform and screened 1,280 compounds. Their goal is to identify the compounds that could lower levels of the protein tau in the brain, which is considered one of the most promising approaches in Alzheimer’s research and could potentially lead to new drugs to treat the disease.
“We showed that we can engineer large quantities of human brain cells that are all the same, while also significantly reducing the costs,” said Wang, Gladstone postdoctoral scholar. “This means our technology can easily be scaled up and can essentially be used to screen millions of compounds.”
A Powerful Tool for the Entire Scientific Community
“We have developed a cost-effective technology to produce large quantities of human brain cells in two simple steps,” summarized Gan. “By surmounting major challenges in human neuron-based drug discovery, we believe this technique will be adopted widely in both basic science and industry.”
Word of this useful new technology has already spread, and people from different scientific sectors have come knocking on Gan’s door to learn about it. Her team has shared the new method with scores of academic colleagues, some of whom had no experience with cell culture. So far, they all successfully repeated the two-step process to produce their own cells and facilitate scientific discoveries.
Details of this new technique were published on October 10, 2017, in the scientific journal Stem Cell Reports.
With some of the roadblocks out of the way, Gan hopes more discoveries will soon help the millions who suffer from Alzheimer’s disease and related conditions.
Learn more: Growing Human Brain Cells in the Lab
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Japanese firms form company aimed at drug discoveryon April 26, 2024 at 5:00 pm
Two big Japanese drug companies, Takeda Pharmaceutical and Astellas Pharma, and a leading bank, Sumitomo Mitsui Banking, are creating a new company focused on accelerating early drug discovery. The ...
- Revealing Protein-Ligand Interactions Using AI Enables Drug Discoveryon April 26, 2024 at 7:34 am
Researchers developed a method to assess the ability of small molecules to bind to hundreds of human proteins using AI and ML.
- AI-Driven Drug Discovery by Pfizer and Austrian Institute Set to Transform Healthcareon April 26, 2024 at 5:38 am
Pfizer, the top pharmaceutical firm, and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed an AI-driven drug discovery method The novel approach, ...
- This Biotech Startup Aims To Speed Up Drug Testing On Animalson April 26, 2024 at 3:29 am
Gordian Biotechnology’s platform allows for potentially hundreds of gene therapies to be tested in an animal at the same time — without harming it.
- After AI protein folding, David Baker’s lab identifies millions of smaller drug candidateson April 25, 2024 at 1:36 pm
A new Science paper from the Baker lab details a novel method for quickly compiling a large library of macrocycle drug candidates.
- A shortcut for drug discovery: Novel method predicts on a large scale how small molecules interact with proteinson April 25, 2024 at 11:00 am
For most human proteins, there are no small molecules known to bind them chemically (so-called "ligands"). Ligands frequently represent important starting points for drug development but this ...
- UW’s Baker Lab researchers make AI strides in drug-like peptideson April 25, 2024 at 10:59 am
In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just small-molecule drugs—by illuminating how proteins fold and interact, all | ...
- AI for drug discovery draws a $1 billion launch—and a lot of hopeon April 25, 2024 at 8:20 am
AI's impact on health care is one area where people are more enthusiastic than anxious—and there's reason to think that enthusiasm is not misplaced.
- The Difference Is the Data: Drug Discovery’s AI Revolutionon April 25, 2024 at 4:00 am
New data-intensive platforms continue to leverage artificial intelligence tools for improved speed and failure rate reductions for drug discovery.
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugson April 24, 2024 at 7:17 pm
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture ...
via Google News and Bing News